Jason M. Redman, M.D.

Jason M. Redman, M.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10, Room 13N240
  • Bethesda, MD 20892
  • 301-496-4000
Center for Immuno-Oncology


Dr. Redman is a physician treating cancer patients with combinations of immunotherapy, chemotherapy and other therapies. He works on clinical trials for patients with prostate cancer, colon cancer, head and neck cancer, and other solid tumors.

The immune system is a complex network traditionally known for fighting infections. However, it can also fight cancer. Cancer immunotherapy refers to drug treatments designed to help the immune system recognize and fight cancer. In some cases, these treatments can lead to significant and long-lasting decreases in cancer burden. Dr. Redman is a member of the Center for Immuno-Oncology (CIO). He works closely with scientists who study the effects of immunotherapy on cancer in the laboratory. This research guides selection of drug combinations for use in clinical trials.

Areas of Expertise

Combination Immunotherapy For Cancer
Therapeutic Cancer Vaccines
Colon Cancer
Prostate Cancer
Immune Checkpoint Inhibitors

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Clinical Trials


Selected Key Publications

Tumor cell HLA class I expression and pathologic response following neoadjuvant immunotherapy for newly diagnosed head and neck cancer

Robbins Y, Friedman J, Redman J, Sievers C, Lassoued W, Gulley JL, Allen CT
Oral Oncology. 138: 106309, 2023. [ Journal Article ]

Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer

Redman JM, Friedman J, Robbins Y, Sievers C, Yang X, Lassoued W, Sinkoe A, Papanicolau-Sengos A, Lee CC, Marte JL, Turkbey E, Mydlarz W, Joshi A, London NR Jr, Pierce M, Taylor R, Hong S, Nguyen A, Soon-Shiong P, Schlom J, Gulley JL, Allen CT
J Clin Invest.. 132(18): e161400, 2022. [ Journal Article ]

A Randomized Phase II Trial of mFOLFOX6 + Bevacizumab Alone or with AdCEA Vaccine + Avelumab Immunotherapy for Untreated Metastatic Colorectal Cancer

Redman JM, Tsai YT, Weinberg BA, Donahue RN, Gandhy S, Gatti-Mays ME, Abdul Sater H, Bilusic M, Cordes LM, Steinberg SM, Marte JL, Jochems C, Kim SS, Marshall JL, McMahon S, Redmond E, Schlom J, Gulley JL, Strauss J
Oncologist. 27(3): 198-209, 2022. [ Journal Article ]

Avelumab in Men With Metastatic Castration- Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine

Madan RA, Redman JM, Karzai F, Dahut WL, Cordes L, Fakhrejahani F, Vu T, Sheikh N, Schlom J, Gulley JL
Journal of Immunotherapy. 1;46(4): 145-151, 2023. [ Journal Article ]


Ad-CEA vaccine plus avelumab vs mFOLFOX6-based standard care in untreated metastatic CRC

ESMO WCGIC 2020 (The Video Journal of Oncology)

In this interview, Dr. Redman discusses the randomized Phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with previously untreated metastatic colorectal cancer. 

QuEST1 clinical trial updates

ESMO 2020 (The Video Journal of Oncology)

In this interview, Dr. Redman gives an overview of his presentation on QuEST1 clinical trial updates including the data and next steps for this therapy. This trial produced an exceptional response rate of 55.6% in unselected, castration-resistant prostate cancer patients.